Irritable Bowel Syndrome Treatment Market Growth, trends, forecast period 2022-2028

Irritable Bowel Syndrome Market syndrome is a division of Telehealth market.

Another report by International Foundation of Gastrointestinal Disorders, mental disorders, suggests that worldwide prevalence rates were 10–15% in 2016.

Same report says that there were around 2.4-3.5 million annual physician visits for IBD in the US alone.

The report also recognizes and analyses the rising trends along with major drivers, challenges and opportunities in the market.

This Hepatic Encephalopathy Treatment Market report provides major statistics on the market status of global and regional manufacturers and is a helpful source of assistance and direction for companies and individuals interested in Healthcare industry.

The company profiles of all the chief and dominating market players and brands who are taking steps such as product launches, joint ventures, mergers and acquisitions are mentioned in the report.Access insightful study with over 100+ pages, list of tables & figures, profiling 10+ companies.

Traditional irritable bowel syndrome therapy typically consists of using medications to suppress the symptoms in those who have been diagnosed with the condition.

The medicine used to treat irritable bowel syndrome is termed as "suppression" or "antibiotic."

The inhibition of the immune system is another untested advantage of this method.Recent research suggests that immunomodulators, a relatively new kind of irritable bowel syndrome therapy, can have a positive effect.

This new family of medicines, which is currently under research, works by influencing the cells that create immune responses to maintain a healthy gut lining.

These cells appear to create a protective response that inhibits the occurrence of diarrhea.

The aim is that this will be a successful long-term treatment for irritable bowel syndrome, and that it may even improve the efficacy of traditional therapies to ease symptoms.

Irritable bowel syndrome (IBS) is a digestive system disorder in which a person experiences multiple symptoms that impacts his/her daily life.

Irritable bowel syndrome affects 10-15% of the population around the world, but the exact cause of IBS is unknown.

The occurrence of IBS is higher in women than in men.

People with a prior digestive tract infection, stressful lifestyle, and family history of IBS are more likely to develop the disorder [NIH].

Irritable bowel syndrome is of three types – irritable bowel syndrome with diarrhea (IBS-D), irritable bowel syndrome with constipation (IBS-C) and irritable bowel syndrome with alternating constipation and diarrhea (IBS-A).

Louis Litt swears by a prunie and just can’t do without it.

We felt after trying it that even if you don’t have Grandma Gertie’s spastic colon you’ll still find it refreshing.

So go ahead and try out this detoxifying prunie recipe!

Research Nester published a report titled “Irritable Bowel Syndrome Drugs Market: Global Demand Analysis & Opportunity Outlook 2029” which delivers detailed overview of the irritable bowel drugs market in terms of market segmentation by type, by product, by end user and by region.Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.The irritable bowel syndrome drug market is anticipated to record a significant CAGR over the forecast period, i.e., 2021 – 2029, owing to the rising geriatric population, increase in the occurrence of gastrointestinal disorders, growing stress levels of people globally, and unhealthy eating habits.

Additionally, escalating advertising campaigns for the treatment of gastrointestinal disorders and increasing usage of over the counter drugs that relieve the symptoms of IBS are other reasons contributing to market growth in the coming years.The market is segmented by type into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C) and mixed IBS (IBS-M), out of which IBS with diarrhea (IBS-D) segment is predicted to hold leading share in the irritable bowel syndrome drugs market on account of rising cases of gastrointestinal disorders such as constipation and diarrhea owing to sedentary lifestyle and increased intake of medications such as linaclotide and lubiprostone worldwide.Download Sample of This Strategic Report: https://www.researchnester.com/sample-request-3040The irritable bowel syndrome drug market is segmented into five main regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The North American region holds the largest market share owing to the availability of cheap fast food and sedentary lifestyle changes of the population.

On the other hand, Asia-Pacific is expected to witness the highest growth during the forecast period on the back of rise in the number of hospitals equipped with specialist surgical services, and growing advancements in healthcare technology.Growth in the Prevalence of Irritable Bowel Syndrome to Boost Market GrowthAs a result of increasing trend of sedentary lifestyle patterns, there has been a hike in the number of cases reporting gastrointestinal disorders which further trigger irritable bowel syndrome.

This has led to the production of new drugs, which are symptom specific, by key market players, which in turn is anticipated to fuel the growth of the market over the forecast period.“The Final Report will cover the impact analysis of COVID-19 on this industry.”Download/Request Sample Copy of Strategic Report:  https://www.researchnester.com/sample-request-3040However, growing completion among major market players is expected to operate as key restraint to the growth of irritable bowel syndrome drugs market in the near future.This report also provides the existing competitive scenario of some of the key players of the irritable bowel syndrome drugs market which includes company profiling of Abbott Services (NYSE: ABT), Ardelyx, Inc. (NASDAQ: ARDX), Astellas Pharma Inc (TYO: 4503), AstraZeneca (LON: AZN), GlaxoSmithKline Plc (LON: GSK), Johnson & Johnson Services, Inc. (NYSE: JNJ), Novartis AG (SWX: NOVN), Ironwood Pharmaceuticals, Inc (NASDAQ: IRWD), Synergy Pharma Consultancy Private Limited, Synthetic Biologics, Inc (NYSEAMERICAN: SYN), and others.

On the whole, the report depicts detailed overview of the global irritable bowel syndrome drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Market Highlights: According to Market Research Future (MRFR)’s new study, the global irritable bowel syndrome treatment market is projected to thrive at a CAGR of 7.58% during the forecast period 2018 to 2023.

It is presumed to scale new heights over the next few years owing to the consolidation of a substantial patient population.The constantly increasing economic burden of IBS affects work productivity and leads to an increase in healthcare costs.

In addition, the large-scale prevalence of anxiety and depression is anticipated to catalyze the growth of the irritable bowel syndrome treatment market over the assessment period.The key players are continually investing in drug development for capitalizing on the rising patient pool.

On the flip side, stringent regulations framed by governments and limited patient satisfaction are predicted to hinder the proliferation of the market during the assessment period.Competitive Dashboard:AbbottAllergan IncArdelyx IncAstellas PharmaIronwood PharmaceuticalsLexicon PharmaceuticalsMallinckrodtNestle Health ScienceSynergy Pharmaceuticals IncValeant Pharmaceuticals InternationalSegmental Analysis:This MRFR report offers a detailed segmental analysis of the global irritable bowel syndrome treatment market based on type, drug type, and end-user.By type, the market has been segmented into IBS-C, IBS-D, and IBS-M.

Among these, IBS-D segment is currently dominating the global market and is projected to retain its dominance in the upcoming years.By drug type, the irritable bowel syndrome treatment market has been segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others.

Among these, the hospital segment accounts for the maximum share of the irritable bowel syndrome treatment market and is presumed to thrive at a comparatively higher CAGR across the review period.Regional Outlook: The Global Irritable Bowel Syndrome Treatment Market, by region, has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa.